IFNA1 and melanoma: Moreover, we were able to correlate STAT1 activation in T cells from HDI treated melanoma patients over the 4-week induction phase to clinical outcome, demonstrating that measuring the IFN signaling patterns in peripheral blood lymphocytes may be useful to select patients who are more likely to benefit from HDI maintenance therapy.